MY203083A - Imidazopyrazine inhibitors of bruton's tyrosine kinase - Google Patents
Imidazopyrazine inhibitors of bruton's tyrosine kinaseInfo
- Publication number
- MY203083A MY203083A MYPI2019003251A MYPI2019003251A MY203083A MY 203083 A MY203083 A MY 203083A MY PI2019003251 A MYPI2019003251 A MY PI2019003251A MY PI2019003251 A MYPI2019003251 A MY PI2019003251A MY 203083 A MY203083 A MY 203083A
- Authority
- MY
- Malaysia
- Prior art keywords
- imidazopyrazine
- bruton
- inhibitors
- tyrosine kinase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
In some embodiments, the invention relates to the compounds of Formula (I) and (II) or a pharmaceutically acceptable salt thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, in some embodiments, the present invention relates to the compounds of Formula (I) and (II), pharmaceutical compositions thereof, and the use of the compounds and pharmaceutical compositions in the treatment of a hyperproliferative disorder, an inflammatory disorder, an immune disorder, or an autoimmune disorder.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437633P | 2016-12-21 | 2016-12-21 | |
| US201762569028P | 2017-10-06 | 2017-10-06 | |
| PCT/IB2017/058319 WO2018116259A1 (en) | 2016-12-21 | 2017-12-21 | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY203083A true MY203083A (en) | 2024-06-07 |
Family
ID=60972291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019003251A MY203083A (en) | 2016-12-21 | 2017-12-21 | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10858364B2 (en) |
| EP (1) | EP3558968B1 (en) |
| JP (1) | JP7022131B2 (en) |
| KR (1) | KR102559851B1 (en) |
| CN (1) | CN110291080B (en) |
| AU (1) | AU2017383236B2 (en) |
| CA (1) | CA3046578A1 (en) |
| CL (1) | CL2019001674A1 (en) |
| ES (1) | ES2856248T3 (en) |
| IL (1) | IL267374B (en) |
| MX (1) | MX388457B (en) |
| MY (1) | MY203083A (en) |
| SA (1) | SA519402217B1 (en) |
| WO (1) | WO2018116259A1 (en) |
| ZA (1) | ZA201903932B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3377488T3 (en) | 2015-11-19 | 2022-10-03 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |
| MY199705A (en) | 2015-12-22 | 2023-11-20 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| TW201808950A (en) | 2016-05-06 | 2018-03-16 | 英塞特公司 | Heterocyclic compounds as immunomodulators |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (en) | 2016-08-29 | 2021-04-28 | Incyte Corp | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS |
| TWI795381B (en) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | Pyrazole derivatives as malt1 inhibitors |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| FI3774791T3 (en) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| BR112020022936A2 (en) | 2018-05-11 | 2021-02-02 | Incyte Corporation | tetrahydro-imidazo [4,5-c] pyridine derivatives as pd-l1 immunomodulators |
| MX2020013899A (en) | 2018-06-18 | 2021-05-27 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors. |
| CN112638878B (en) | 2018-08-29 | 2025-07-22 | 安塞塔制药公司 | Process for preparing Ala-b |
| BR112021019799A2 (en) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivatives containing pyridine rings as malt1 inhibitors |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| MX2022003578A (en) | 2019-09-30 | 2022-05-30 | Incyte Corp | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS. |
| BR112022009031A2 (en) | 2019-11-11 | 2022-10-11 | Incyte Corp | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR |
| CN114075190A (en) * | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | Heterocyclic BTK inhibitors |
| MX2023005362A (en) | 2020-11-06 | 2023-06-22 | Incyte Corp | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof. |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| TW202233615A (en) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Crystalline form of a pd-1/pd-l1 inhibitor |
| CN114807038B (en) * | 2022-02-11 | 2023-11-10 | 四川大学华西第二医院 | Mouse lymphoma related fibroblast tumor cell HXLyAF-KT and application thereof |
| EP4631503A1 (en) * | 2024-04-08 | 2025-10-15 | Molius Saglik Teknolojileri Anonim Sirketi | Avl-292 or mk-5108 for use in the treatment of pdac |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2201840E (en) * | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | BRUTON TYROSINE KINASE INHIBITORS |
| SG175195A1 (en) * | 2009-04-16 | 2011-11-28 | Ct Nac Investigaciones Oncologicas Cnio | Imidazopyrazines for use as kinase inhibitors |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| WO2013010869A1 (en) | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
| JP5826931B2 (en) | 2011-07-19 | 2015-12-02 | メルク・シャープ・エンド・ドーム・ベー・フェー | 4-Imidazopyridazin-1-yl-benzamide and 4-Imidazotriazin-1-yl-benzamide as BTK inhibitors |
| US10328080B2 (en) * | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
| WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| US20170231995A1 (en) * | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
| WO2016106623A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
| WO2016106627A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| EP3310776A4 (en) * | 2015-06-02 | 2019-01-16 | Pharmacyclics LLC | INHIBITORS OF BRUTON TYROSINE KINASE |
-
2017
- 2017-12-21 ES ES17829328T patent/ES2856248T3/en active Active
- 2017-12-21 CA CA3046578A patent/CA3046578A1/en active Pending
- 2017-12-21 MY MYPI2019003251A patent/MY203083A/en unknown
- 2017-12-21 KR KR1020197020718A patent/KR102559851B1/en active Active
- 2017-12-21 EP EP17829328.8A patent/EP3558968B1/en active Active
- 2017-12-21 WO PCT/IB2017/058319 patent/WO2018116259A1/en not_active Ceased
- 2017-12-21 AU AU2017383236A patent/AU2017383236B2/en active Active
- 2017-12-21 MX MX2019007156A patent/MX388457B/en unknown
- 2017-12-21 JP JP2019533229A patent/JP7022131B2/en active Active
- 2017-12-21 US US16/448,056 patent/US10858364B2/en active Active
- 2017-12-21 CN CN201780086892.3A patent/CN110291080B/en active Active
-
2019
- 2019-06-16 IL IL267374A patent/IL267374B/en unknown
- 2019-06-18 ZA ZA2019/03932A patent/ZA201903932B/en unknown
- 2019-06-18 CL CL2019001674A patent/CL2019001674A1/en unknown
- 2019-06-19 SA SA519402217A patent/SA519402217B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110291080B (en) | 2022-07-08 |
| JP2020514264A (en) | 2020-05-21 |
| SA519402217B1 (en) | 2022-04-19 |
| BR112019012604A2 (en) | 2019-11-26 |
| AU2017383236A1 (en) | 2019-06-27 |
| US10858364B2 (en) | 2020-12-08 |
| WO2018116259A1 (en) | 2018-06-28 |
| ES2856248T3 (en) | 2021-09-27 |
| KR102559851B1 (en) | 2023-07-25 |
| MX2019007156A (en) | 2019-09-05 |
| ZA201903932B (en) | 2021-01-27 |
| US20190345164A1 (en) | 2019-11-14 |
| KR20190095403A (en) | 2019-08-14 |
| CA3046578A1 (en) | 2018-06-28 |
| IL267374B (en) | 2021-07-29 |
| CL2019001674A1 (en) | 2019-11-08 |
| AU2017383236B2 (en) | 2022-02-10 |
| EP3558968A1 (en) | 2019-10-30 |
| JP7022131B2 (en) | 2022-02-17 |
| EP3558968B1 (en) | 2021-02-03 |
| CN110291080A (en) | 2019-09-27 |
| MX388457B (en) | 2025-03-20 |
| IL267374A (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519402217B1 (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| PH12022550098A1 (en) | Parp1 inhibitors | |
| MX2021004639A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors. | |
| MX2017015574A (en) | Inhibitors of bruton's tyrosine kinase. | |
| MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| MX2021000071A (en) | Use of pridopidine to improve cognitive function and for treating alzheimer's disease. | |
| EA201891229A1 (en) | EIF4A-INHIBITING COMPOUNDS AND RELATED METHODS | |
| EA201790951A1 (en) | DERIVATIVES OF HYDROXYLKYL SUBSTITUTED PHENILTRIASOLE AND THEIR USE | |
| NZ722326A (en) | Tricyclic compounds as anticancer agents | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| EA201891050A1 (en) | COMPOUNDS PYRROLO, PYRAZOLO, IMIDAZOPYRIMIDINE AND PYRIDINE THAT INHIBIT MNK1 AND MNK2 | |
| WO2016109217A3 (en) | Btk inhibitors | |
| TW201613577A (en) | Pharmaceutical combinations | |
| SI3609886T1 (en) | BENZOAZEPINE ANALOGUES AS BRUTON'S TYROSINE KINASE INHIBITORS | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| LT3972604T (en) | BRUTON'S TYROSINE KINASE INHIBITOR FOR USE IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICA | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| MX2020000402A (en) | Novel substituted xanthine derivatives. | |
| PH12019501999A1 (en) | Pyrazole derivatives as bromodomain inhibitors | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2021015333A (en) | Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer. | |
| NZ755637A (en) | Compounds and their use in the treatment of schistosomiasis |